News
Metabolon Identifies Preterm Labor Biomarkers
News
Metabolon Identifies Preterm Labor Biomarkers
Read time:
Want a FREE PDF version of This News Story?
Complete the form below and we will email you a PDF version of "Metabolon Identifies Preterm Labor Biomarkers"
First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?
Metabolon, Inc. announces the publication of “Metabolomics in premature labor: a novel approach to identify patients at risk for preterm delivery”, in The Journal of Maternal-Fetal and Neonatal Medicine.
The study, carried out in collaboration with co-authors Dr. Roberto Romero and colleagues of the NICHD, NIH, and DHHS, aimed to identify prognostic and diagnostic biomarkers of preterm delivery in women with spontaneous preterm labor (PTL) and intact membranes. Spontaneous preterm labor does not always lead to preterm delivery and rapid identification of the risk of preterm delivery to pregnant women with PTL is needed for physicians to make immediate patient management decisions.
The report describes the identification of biomarkers for PTL and delivery and concludes that the risk of preterm delivery, in the presence or absence of infection and inflammation, can be assessed by metabolic profiling of amniotic fluid.
In addition, the report presents a preliminary draft of the human amniotic fluid metabolome from women with PTL that shows biochemical intermediates of human metabolism as well as xenobiotics such as salicylamide and bacterial products can be measured in human amniotic fluid.
The study, carried out in collaboration with co-authors Dr. Roberto Romero and colleagues of the NICHD, NIH, and DHHS, aimed to identify prognostic and diagnostic biomarkers of preterm delivery in women with spontaneous preterm labor (PTL) and intact membranes. Spontaneous preterm labor does not always lead to preterm delivery and rapid identification of the risk of preterm delivery to pregnant women with PTL is needed for physicians to make immediate patient management decisions.
The report describes the identification of biomarkers for PTL and delivery and concludes that the risk of preterm delivery, in the presence or absence of infection and inflammation, can be assessed by metabolic profiling of amniotic fluid.
In addition, the report presents a preliminary draft of the human amniotic fluid metabolome from women with PTL that shows biochemical intermediates of human metabolism as well as xenobiotics such as salicylamide and bacterial products can be measured in human amniotic fluid.
Advertisement
